Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM2YIOE)

Drug Name
SDZ-MAR-327 Drug Info
Indication
Disease Entry ICD 11 Status REF
Psychotic disorder 6A20-6A25 Phase 2 [1]
Schizophrenia 6A20 Terminated [1]
Cross-matching ID
PubChem CID
56603721
TTD Drug ID
DM2YIOE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Modulator [2]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
5-HT 1A receptor (HTR1A) DTT HTR1A 4.661 5.289 3.053 3.472
Dopamine D2 receptor (D2R) DTT DRD2 5.345 5.634 5.789 5.901
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Psychotic disorder
ICD Disease Classification 6A20-6A25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 1A receptor (HTR1A) DTT HTR1A 5.70E-01 -0.13 -0.53
Dopamine D2 receptor (D2R) DTT DRD2 2.20E-03 -0.51 -1.35
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
2 DOI: 10.1038/sj.mp.4002062